In contrast, T cell-specific deletion of Ptpn11 does not improve T cell anti-tumour responses [55], indicating that the effects of PTPN11 inhibitors on T cell responses in cancer settings are likely to be indirect and secondary to the modulation of myeloid cell phenotypes. The gene discussed is PTPN11; the disease is neoplasm.